Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1925 1
1934 1
1939 2
1940 1
1941 1
1943 1
1946 4
1947 2
1948 1
1949 4
1950 1
1951 4
1952 2
1953 2
1954 3
1955 2
1956 2
1957 2
1958 1
1959 1
1960 1
1961 3
1962 1
1964 2
1966 2
1969 1
1972 4
1974 2
1975 3
1977 4
1978 4
1979 2
1980 2
1981 3
1982 5
1983 6
1984 3
1985 1
1986 5
1987 3
1988 2
1989 1
1991 6
1992 1
1993 7
1994 3
1995 2
1996 1
1997 3
1998 1
2000 3
2001 1
2002 1
2003 4
2004 1
2005 5
2006 2
2007 2
2008 4
2009 7
2010 6
2011 7
2012 7
2013 10
2014 8
2015 10
2016 14
2017 22
2018 20
2019 12
2020 25
2021 25
2022 15
2023 13
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for obrien h
Search for Obritin H instead (1 results)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Pharmacology: Non-Insulin Agents.
O'Brien H, Travis C. O'Brien H, et al. Prim Care. 2022 Jun;49(2):315-326. doi: 10.1016/j.pop.2021.11.010. Epub 2022 Apr 22. Prim Care. 2022. PMID: 35595485 Review.
Bronchopleurocutaneous Fistula.
O'Brien H, Franciosi AN, Murphy DJ, McCarthy C. O'Brien H, et al. Am J Respir Crit Care Med. 2023 Nov 15;208(10):1126-1128. doi: 10.1164/rccm.202303-0390IM. Am J Respir Crit Care Med. 2023. PMID: 37487112 No abstract available.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Breaking the performance ceiling for neoantigen immunogenicity prediction.
O'Brien H, Salm M, Morton LT, Szukszto M, O'Farrell F, Boulton C, Becker PD, Samuels Y, Swanton C, Mansour MR, Reker Hadrup S, Quezada SA. O'Brien H, et al. Nat Cancer. 2023 Dec;4(12):1618-1621. doi: 10.1038/s43018-023-00675-z. Nat Cancer. 2023. PMID: 38102360 No abstract available.
338 results